In this study, we also describe the clinical validation of the FoundationOne Liquid CDx assay, including large-scale comparisons with orthogonal clinical plasma- and tissue-genotyping methods, for both EGFR in NSCLC and PIK3CA in breast cancer. The gene discussed is EGFR; the disease is breast carcinoma.